申请人:——
公开号:US20020019343A1
公开(公告)日:2002-02-14
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS—, HO— or H
2
N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5′-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=—NH
2
, —OH, —COOH, —O—CO—R—COR*, —NH—CO—R—COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.
转铁蛋白、白蛋白和聚
乙二醇的共轭物,包括具有至少一个HS—、HO—或
H2N基团的天然或
硫醇化的
转铁蛋白或白蛋白或聚
乙二醇(分子量约在5,000至20,000之间),以及通过马来
酰亚胺或N-羟基琥珀
酰亚胺酯类化合物衍生的细胞毒素化合物,如
多柔比星、多诺西星、依
吡螺星、伊达鲁比汀、米托
蒽醌、
氯乙酰胺、
甲氨蝶呤、5-
氟尿
嘧啶、5'-脱氧-5-
氟尿
嘧啶、
硫鸟嘌呤、
甲氨蝶呤、
紫杉醇、
多西他赛、托泊替尼、
9-氨基喜树碱、
依托泊苷、
替尼泊苷、米托泼苷、
长春新碱、长春烷醇、长春烯胺、长春诺宾或A、B、C或D通式的化合物,其中n=0-6,X=-NH2、-OH、-COOH、-O-CO-R-COR*、-NH-CO-R-COR*,其中R是具有1-6个碳原子的脂肪族碳链或取代或未取代的苯基基团,R*是氢、苯基或具有1-6个碳原子的烷基。